Adagene Inc. (ADAG)
D
Pipeline Grade
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-10-31 | Phase2 Readout | — |
| 2026-12-31 | Phase2 Readout | — |
Active Clinical Trials (6)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer | PHASE2 | Recruiting | 51 |
| NCT04524871 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advan... | PHASE2 | Recruiting | 518 |
| NCT05405595 | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | PHASE2 | Recruiting | 186 |
| NCT06846268 | Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer | PHASE2 | Recruiting | 20 |
| NCT05275777 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Neg... | PHASE2 | Active Not Recruiting | 66 |
| NCT05614258 | Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors | PHASE1 | Active Not Recruiting | 14 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.